138 related articles for article (PubMed ID: 22411019)
1. A review of the medical treatment of pediatric glaucomas at Moorfields Eye Hospital.
Chang L; Ong EL; Bunce C; Brookes J; Papadopoulos M; Khaw PT
J Glaucoma; 2013; 22(8):601-7. PubMed ID: 22411019
[TBL] [Abstract][Full Text] [Related]
2. Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines.
Stewart WC; Konstas AG; Nelson LA; Kruft B
Ophthalmology; 2008 Jul; 115(7):1117-1122.e1. PubMed ID: 18082886
[TBL] [Abstract][Full Text] [Related]
3. An eight-week, multicentric, randomized, interventional, open-label, phase 4, parallel comparison of the efficacy and tolerability of the fixed combination of timolol maleate 0.5%/brimonidine tartrate 0.2% versus fixed combination of timolol maleate 0.5%/dorzolamide 2% in patients with elevated intraocular pressure.
Hatanaka M; Grigera DE; Barbosa WL; Jordao M; Susanna R
J Glaucoma; 2008 Dec; 17(8):674-9. PubMed ID: 19092465
[TBL] [Abstract][Full Text] [Related]
4. Comparison of latanoprost and timolol in pediatric glaucoma: a phase 3, 12-week, randomized, double-masked multicenter study.
Maeda-Chubachi T; Chi-Burris K; Simons BD; Freedman SF; Khaw PT; Wirostko B; Yan E;
Ophthalmology; 2011 Oct; 118(10):2014-21. PubMed ID: 21680022
[TBL] [Abstract][Full Text] [Related]
5. Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension.
Orzalesi N; Rossetti L; Invernizzi T; Bottoli A; Autelitano A
Invest Ophthalmol Vis Sci; 2000 Aug; 41(9):2566-73. PubMed ID: 10937568
[TBL] [Abstract][Full Text] [Related]
6. Additive intraocular pressure reduction effect of fixed combination of maleate timolol 0.5%/dorzolamide 2% (Cosopt) on monotherapy with latanoprost (Xalatan) in patients with elevated intraocular pressure: a prospective, 4-week, open-label, randomized, controlled clinical trial.
Hatanaka M; Reis A; Sano ME; Susanna R
J Glaucoma; 2010; 19(5):331-5. PubMed ID: 19730119
[TBL] [Abstract][Full Text] [Related]
7. Intraocular pressure lowering effect of dorzolamide/timolol fixed combination in patients with glaucoma who were unresponsive to prostaglandin analogs/prostamides.
Martínez A; Sánchez M
Curr Med Res Opin; 2007 Mar; 23(3):595-9. PubMed ID: 17355740
[TBL] [Abstract][Full Text] [Related]
8. Three-month, randomized, parallel-group comparison of brimonidine-timolol versus dorzolamide-timolol fixed-combination therapy.
Nixon DR; Yan DB; Chartrand JP; Piemontesi RL; Simonyi S; Hollander DA
Curr Med Res Opin; 2009 Jul; 25(7):1645-53. PubMed ID: 19476406
[TBL] [Abstract][Full Text] [Related]
9. Circadian intraocular pressure control with dorzolamide versus timolol maleate add-on treatments in primary open-angle glaucoma patients using latanoprost.
Tamer C; Oksüz H
Ophthalmic Res; 2007; 39(1):24-31. PubMed ID: 17164574
[TBL] [Abstract][Full Text] [Related]
10. Effects of topical hypotensive drugs on circadian IOP, blood pressure, and calculated diastolic ocular perfusion pressure in patients with glaucoma.
Quaranta L; Gandolfo F; Turano R; Rovida F; Pizzolante T; Musig A; Gandolfo E
Invest Ophthalmol Vis Sci; 2006 Jul; 47(7):2917-23. PubMed ID: 16799034
[TBL] [Abstract][Full Text] [Related]
11. Effect of treatment by medicine or surgery on intraocular pressure and pulsatile ocular blood flow in normal-pressure glaucoma.
Poinoosawmy D; Indar A; Bunce C; Garway-Heath DF; Hitchings RA
Graefes Arch Clin Exp Ophthalmol; 2002 Sep; 240(9):721-6. PubMed ID: 12271368
[TBL] [Abstract][Full Text] [Related]
12. A comparison of the effects of dorzolamide/timolol fixed combination versus latanoprost on intraocular pressure and pulsatile ocular blood flow in primary open-angle glaucoma patients.
Janulevicienë I; Harris A; Kagemann L; Siesky B; McCranor L
Acta Ophthalmol Scand; 2004 Dec; 82(6):730-7. PubMed ID: 15606472
[TBL] [Abstract][Full Text] [Related]
13. Fixed-combination brimonidine-timolol versus latanoprost in glaucoma and ocular hypertension: a 12-week, randomized, comparison study.
Katz LJ; Rauchman SH; Cottingham AJ; Simmons ST; Williams JM; Schiffman RM; Hollander DA
Curr Med Res Opin; 2012 May; 28(5):781-8. PubMed ID: 22458918
[TBL] [Abstract][Full Text] [Related]
14. Dorzolamide/timolol combination versus concomitant administration of brimonidine and timolol: six-month comparison of efficacy and tolerability.
Sall KN; Greff LJ; Johnson-Pratt LR; DeLucca PT; Polis AB; Kolodny AH; Fletcher CA; Cassel DA; Boyle DR; Skobieranda F
Ophthalmology; 2003 Mar; 110(3):615-24. PubMed ID: 12623832
[TBL] [Abstract][Full Text] [Related]
15. Experience with COSOPT, the fixed combination of timolol and dorzolamide, gained in Swiss ophthalmologists' offices.
Pajic B;
Curr Med Res Opin; 2003; 19(2):95-101. PubMed ID: 12740152
[TBL] [Abstract][Full Text] [Related]
16. Ocular hypotensive effects and safety over 3 months of switching from an unfixed combination to latanoprost 0.005%/timolol maleate 0.5% fixed combination.
Inoue K; Okayama R; Higa R; Sawada H; Wakakura M; Tomita G
J Ocul Pharmacol Ther; 2011 Dec; 27(6):581-7. PubMed ID: 22011049
[TBL] [Abstract][Full Text] [Related]
17. Brimonidine tartrate 0.15%, dorzolamide hydrochloride 2%, and brinzolamide 1% compared as adjunctive therapy to prostaglandin analogs.
Bournias TE; Lai J
Ophthalmology; 2009 Sep; 116(9):1719-24. PubMed ID: 19592108
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of brimonidine and dorzolamide for intraocular pressure lowering in glaucoma and ocular hypertension.
Katz LJ; Simmons ST; Craven ER
Curr Med Res Opin; 2007 Dec; 23(12):2971-83. PubMed ID: 17949534
[TBL] [Abstract][Full Text] [Related]
19. A randomized, investigator-masked, 4-week study comparing timolol maleate 0.5%, brinzolamide 1%, and brimonidine tartrate 0.2% as adjunctive therapies to travoprost 0.004% in adults with primary open-angle glaucoma or ocular hypertension.
Reis R; Queiroz CF; Santos LC; Avila MP; Magacho L
Clin Ther; 2006 Apr; 28(4):552-9. PubMed ID: 16750466
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness and safety of dorzolamide-timolol alone or combined with latanoprost in open-angle glaucoma or ocular hypertension.
Lesk MR; Koulis T; Sampalis F; Sampalis JS; Bastien NR
Ann Pharmacother; 2008 Apr; 42(4):498-504. PubMed ID: 18364402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]